English

Lytix Biopharma to present at ABG Sundal Collier Life Science Summit and Redeye Growth Day in Stockholm

Report this content

Oslo, 25 May 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company – is pleased to announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, will be presenting the company at two events in Stockholm next week.

  • The ABG Sundal Collier Life Science Summit, Wednesday 31 May at 11:30 CET 
  • Redeye Growth Day 2023, Thursday 1 June at 12:55 CET

A prerecorded Lytix presentation for Redeye Growth Day is available at https://www.redeye.se/video/company-prerecorded-presentation/911051/lytix-biopharma

For more information, please contact:

Ole Peter Nordby, Head of IR: ole.peter.nordby@lytixbiopharma.com

Lytix Biopharma in brief

Based in Oslo, Norway, Lytix Biopharma is a clinical stage immune-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 target cancer cells and disintegrate their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens.  This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.

Subscribe